Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975974 | 1.00 | KMT2A (0.51) | KMT2ADHFRMEP1BBCHEKDM4E | |
| SCHEMBL13541357 | 0.91 | TSHR (0.51) | DHFRCYP2D6TSHRGGPS1 | |
| SCHEMBL13672772 | 0.88 | MAOB (0.46) | BCHEKDM4EALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL9308504 | 0.88 | TSHR (0.61) | DHFRCYP2D6TSHRGGPS1 | |
| SCHEMBL31261689 | 0.88 | TSHR (0.61) | DHFRCYP2D6TSHRGGPS1 | |
| SCHEMBL2937407 | 0.85 | TP53 (0.55) | DHFRBCHEKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL59488 | 0.85 | KDM4E (0.61) | KMT2ADHFRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29976345 | 0.85 | TP53 (0.55) | DHFRBCHEKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL7254138 | 0.85 | PRSS1 (0.47) | DHFRKDM4EALDH1A1TSHRGGPS1 | |
| SCHEMBL2062788 | 0.84 | KDM4E (0.50) | BCHEKDM4EALDH1A1SMN1; SMN2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| CN-110023292-B | Apoptosis inhibitors | 北京生命科学研究所 | 2022-10-04 | — | — | CN | disclosed |
| US-20210309647-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-10-07 | — | — | US | disclosed |
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-20190152960-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20140073634-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) | 2014-03-13 | — | — | US | disclosed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152960-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | KMT2A 3060/4885DHFR 244/4885MEP1B 2581/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | KMT2A 3060/4885DHFR 244/4885MEP1B 2581/4885 |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | KMT2A 3722/4885DHFR 532/4885MEP1B 371/4885 |
| US-20140073634-A1 | HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, HIF1A, EGLN3 | KMT2A 1042/4885DHFR 284/4885MEP1B 1728/4885 |
| US-11034680-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | KMT2A 3060/4885DHFR 244/4885MEP1B 2581/4885 |
| US-20210309647-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | KMT2A 3060/4885DHFR 244/4885MEP1B 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.